Boston Scientific (BSX) is a top mid-cap growth stock, but Oppenheimer questions its $14.5B Penumbra acquisition valuation, potentially impacting ROIC. The deal marks BSX’s re-entry into the neurovascular market and aims to enhance its revenue and margins long term.
Penumbra’s acquisition broadens Boston Scientific’s cardiovascular and neurovascular portfolios, positioning the company for growth. The deal is expected to be slightly dilutive to BSX’s EPS initially but turn accretive in the long term, projecting ~$1.4B in sales for FY 2025 post-acquisition. BSX develops medical devices in MedSurg and Cardiovascular segments.
While BSX shows investment potential, some AI stocks may offer greater upside with lower risk. For opportunities in the AI sector, consider looking into undervalued stocks benefiting from current economic trends. Check out our report for insights on the best short-term AI stock picks.

Read more at Yahoo Finance: Oppenheimer Questions Valuation of Boston Scientific’s $14.5 Billion Penumbra Deal